"Why Do Follicles Fail to Grow Despite Urinary Gonadotropin Injection in Polycystic Ovary Syndrome?"

Update Date: 2024-10-24 Source: Network

Polycystic Ovary Syndrome and Urinary Gonadotropin Injection

Polycystic refers to Polycystic Ovary Syndrome (PCOS). Urinary Gonadotropin Injection is a medication commonly prescribed for fertility treatment. In cases where patients with PCOS do not experience follicle growth after administering Urinary Gonadotropin Injection, common reasons include short duration of medication, low dosage, insensitivity to the drug, hormonal imbalance, obesity, among others. It is crucial to promptly revisit the healthcare provider for reassessment and follow their instructions for further management.

1. Short Duration of Medication: Urinary Gonadotropin Injection takes time to produce noticeable effects. If only administered for a couple of times, the follicles may not show significant growth upon examination. Continuing the medication is recommended.

2. Low Dosage: Adequate dosage, as prescribed by the doctor, is necessary for optimal results. A low dosage may lead to inadequate effects. Dosage adjustment should be made under the guidance of a healthcare provider.

3. Insensitivity to the Drug: Due to individual constitution, some patients may not respond well to this medication. In such cases, switching to another ovulation-inducing drug in the next cycle can be considered.

4. Hormonal Imbalance: In severe cases of PCOS, hormonal imbalance may persist despite treatment. Attempting ovulation induction with Urinary Gonadotropin Injection without prior hormonal regulation may yield unsatisfactory results. First, hormonal balance can be achieved through medications like Drospirenone and Ethinyl Estradiol Tablets or Desogestrel and Ethinyl Estradiol Tablets, followed by ovulation induction when stable.

5. Obesity: Obesity can diminish the effectiveness of this medication. Weight loss through dieting and exercise is advisable before attempting ovulation induction again. This scenario also warrants consideration of congenital ovarian developmental abnormalities. Therefore, management should be tailored to the underlying cause under medical supervision to avoid severe consequences.